Nerviano Medical Sciences S.r.l. to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC 2023: Poster
October 12, 2023

Nerviano Medical Sciences Presents Preliminary, Encouraging Clinical Phase 1 Data for PARP-1 Selective Inhibitor at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

NERVIANO, IT and BOSTON, Mass, October 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, reported today, initial results from the dose escalation parts of two Phase I-I/II studies for NMS-03305293 (NMS-293). As an oral, brain penetrant PARP-1 selective inhibitor, NMS-293 has shown strong antitumor activity and complete tumor regression in BRCA mutated preclinical models as a single agent. NMS-293 shows remarkable selectivity towards PARP-1 and efficiently inhibits cellular PARP activity resulting in selective antiproliferative responses on BRCA mutated cell lines. Furthermore, NMS-293 is synergistic and well tolerated in combination with temozolomide (TMZ) in both MGMT methylated and MGMT unmethylated glioblastoma mouse models. For the first time, clinical data is being presented during the poster session (Abstract 37568) at the AACR-NCI-EORTC 2023 Annual Meeting in Boston, Massachusetts. The poster will be available today on the NMS websites.

“The data presented today shows NMS-293 is well tolerated and exhibits early signs of clinical activity, that together could provide future treatment options in areas of high unmet medical need in many non-BRCA-mutation tumors, including glioblastoma” stated Lisa Mahnke, MD, PhD, Chief Medical Officer for Nerviano Medical Sciences. NMS-293 showed encouraging clinical activity in combination with TMZ in difficult-to-treat, recurrent glioma patients. Investigator assessed clinical activity included two patients with relapsed glioma experiencing partial responses by RANO criteria as well as one patient with relapsed glioblastoma having disappearance of a non-measurable lesion.

NMS-293 is being evaluated in two Phase I-I/II dose-escalation/expansion studies assessing safety, tolerability, and preliminary antitumor activity. In PARPA-293-001 (NCT04182516), NMS-293 has been administered orally in dose escalation as a single agent, in adult patients with selected advanced/metastatic, relapsed/refractory solid tumors who have exhausted standard treatment options. An MTD has been identified at 100 mg BID for 28 days on 28-day cycle, a dose providing exposure in a meaningful, active range relative to preclinical predictions. PARPA-293-002 (NCT04910022) is a Phase I/II trial in which NMS-293 was administered in dose escalation, on days 1-7, together with TMZ for the first 5 days of each cycle, in repeated 28-day cycles in adult patients with recurrent diffuse gliomas who failed prior standard of care. The Phase II expansion will focus on glioblastoma. “I am so proud of our NMS team; NMS was the first company to crack PARP-1 biology and bring a PARP-1 selective inhibitor into the clinic. Furthermore, NMS is the first company to have a brain penetrant PARP-1 in clinical development. The initial clinical data presented in glioma is the first demonstration of our therapeutic hypothesis that a PARP-1 inhibitor can be combined with chemotherapy such as TMZ paving the way for indications outside of BRCA mutant tumors,” stated Hugues Dolgos, PharmD, Chief Executive Officer for NMS Group.

To date, no DLTs in PARPA-293-002 have been characterized, and overall, NMS-293 was well tolerated with no trends of myelosuppression. The unpooled safety database at the data-cut-off includes 45 patients in PARPA-293-001 and 21 patients in PARPA-293-002. The most frequent (≥10%) any-grade treatment related adverse events (TRAEs) in PARPA-293-001 were reversible QTcF prolongation, nausea, asthenia, decreased appetite and vomiting, mainly mild/moderate. In PARPA-293-002, no TRAEs above grade 3 were reported and the most frequent (≥10%) any-grade TRAEs were: nausea, fatigue, vomiting, decreased appetite, and decreased platelet count, mainly grade 1 adverse events.

Link PR:2023 10 12 PARP ENA Poster Press Rel Final

Poster : NMS PARP ENA Poster


Welcome and Check out our new motion picture!